CRSP (CRISPR Therapeutics AG) Projected Sales Volume

crisprtx.com - graphic logo of issuer CRSP

Sales volume expectations for CRISPR Therapeutics AG demonstrate growth potential, where the value of 0.03 aligns with the current metric. This trend is driven by expansion into the untapped gene therapy market for rare blood pathologies. The success of CRISPR Therapeutics AG is based on the ownership of key Cas9 method patents and the creation of the drug Casgevy. Market capitalization relies on licensing payments and grants for the development of innovative medicines.

Company Future Revenue: CRISPR (CRSP) for 07/04/2022 - 11/18/2026

CRISPR Therapeutics Corp - analytical breakdowns and key metrics (CRSP)

Analysis of all company metrics:crisprtx.com CRSP
Signature product of CRISPR Therapeutics Inc

This metric synthesizes real transaction data with commodity and bond market dynamics to determine the issuer's expected revenue. By analyzing the projected sales figures of CRISPR Therapeutics AG (CRSP), investors assess the capitalization potential of CRISPR Therapeutics AG (CRSP), taking into account the impact of high R&D expenditures and the complexities regarding insurance reimbursement for expensive gene therapies.

Analysis of competing companies

Company Future Sales Volume TEM (Tempus AI)|Company Future Sales Qiagen Group|Company Projected Revenue Ionis Pharma IONS|RGEN - Company Future Sales Volume|RNA - Company Projected Revenue|Company Future Sales genedx.com WGS|Ultragenyx Pharmaceutical (RARE) - Company Projected Revenue|Company Expected Sales Volume Beam Therapeutics Corp (BEAM)|SRPT (Sarepta Therapeutics) - Projected Sales Volume|Company Expected Sales Volume Twist Bioscience Corp TWST|Projected Sales Volume TXG|Projected Sales Volume intelliatx.com (NTLA)|Stoke Therapeutics - Company Future Sales Volume|BioLife Solutions Inc (BLFS) - Company Expected Sales Volume|wavelifesciences.com - Projected Sales Volume|Maze Therapeutics Corp (MAZE) - Company Future Sales Volume|SION: Projected Sales Volume|Company Revenue Forecast PRME|Company Projected Revenue Taysha Gene Therapies|Company Revenue Forecast QURE (uniQure)|Company Projected Revenue MeiraGTx (MGTX)|REGENXBIO Corp - Company Revenue Forecast|Company Projected Revenue Solid Biosciences SLDB|OCGN - Company Future Sales Volume|pacb.com - Projected Sales Volume|Benitec (BNTC) - Company Future Sales Volume|DSGN: Projected Sales Volume|RCKT - Company Future Sales|FDMT: Company Future Sales|Company Revenue Forecast LXEO (lexeotx.com)|Company Projected Revenue Korro Bio Inc. (KRRO)|Company Projected Revenue Volume EDIT|Projected Sales Volume SLN (Silence Therapeutics PLC)|Company Future Revenue PRQR|CDXS - Company Projected Revenue|SGMO (Sangamo Therapeutics) - Company Revenue Forecast|NAUT: Projected Sales Volume|Company Revenue Forecast MGX|DTIL (precisionbiosciences.com) - Projected Sales Volume|Company Revenue Forecast GBIO (Generation Bio Co.)|Company Projected Revenue Boundless Bio (BOLD)|Exicure - Company Revenue Forecast|Projected Sales Volume IMNN (imunon.com)|Company Future Sales Phio Pharmaceuticals (PHIO)|MBIO: Company Future Sales Volume|Company Future Revenue RNAZ (transcodetherapeutics.com)|Bionano Genomics, Inc. (BNGO) - Company Projected Revenue|APDN - Company Future Sales|Company Future Sales Volume BLUE|Projected Sales Volume immunoprecise.com|Projected Sales Volume OMGA|Company Future Sales Singular Genomics Corp|Regulus Therapeutics - Company Future Sales Volume|SYRS (Syros Pharmaceuticals) - Company Expected Revenue|Telesis Bio Inc. - Projected Sales Volume|Company Future Revenue TCON (TRACON Pharmaceuticals Inc.)|UBX: Projected Sales Volume